SE0401631L - Ny sammansättning - Google Patents

Ny sammansättning

Info

Publication number
SE0401631L
SE0401631L SE0401631A SE0401631A SE0401631L SE 0401631 L SE0401631 L SE 0401631L SE 0401631 A SE0401631 A SE 0401631A SE 0401631 A SE0401631 A SE 0401631A SE 0401631 L SE0401631 L SE 0401631L
Authority
SE
Sweden
Prior art keywords
new composition
treatment
composition
prophylaxis
disclosed
Prior art date
Application number
SE0401631A
Other languages
English (en)
Other versions
SE528337C2 (sv
SE0401631D0 (sv
Inventor
Bjoern Andersch
Inger Mattsby-Baltzer
Original Assignee
Skog Och Sjoe I Vaermland Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skog Och Sjoe I Vaermland Ab filed Critical Skog Och Sjoe I Vaermland Ab
Priority to SE0401631A priority Critical patent/SE528337C2/sv
Publication of SE0401631D0 publication Critical patent/SE0401631D0/sv
Priority to ZA200703166A priority patent/ZA200703166B/xx
Priority to KR1020077001696A priority patent/KR20070048170A/ko
Priority to NZ552764A priority patent/NZ552764A/en
Priority to DE602005020639T priority patent/DE602005020639D1/de
Priority to US11/628,664 priority patent/US20080161234A1/en
Priority to PCT/SE2005/000989 priority patent/WO2006001766A1/en
Priority to RU2007102273/15A priority patent/RU2398575C2/ru
Priority to BRPI0512503-0A priority patent/BRPI0512503A/pt
Priority to CA002571183A priority patent/CA2571183A1/en
Priority to EP05755054A priority patent/EP1784176B1/en
Priority to JP2007518008A priority patent/JP2008503576A/ja
Priority to CNA2005800206978A priority patent/CN1972683A/zh
Priority to AU2005257722A priority patent/AU2005257722B2/en
Priority to AT05755054T priority patent/ATE464045T1/de
Publication of SE0401631L publication Critical patent/SE0401631L/sv
Publication of SE528337C2 publication Critical patent/SE528337C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE0401631A 2004-06-23 2004-06-23 Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet SE528337C2 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE0401631A SE528337C2 (sv) 2004-06-23 2004-06-23 Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet
AT05755054T ATE464045T1 (de) 2004-06-23 2005-06-23 Zusammensetzung aus milchsäure und lactoferrin
PCT/SE2005/000989 WO2006001766A1 (en) 2004-06-23 2005-06-23 Composition comprising lactic acid and lactoferrin
BRPI0512503-0A BRPI0512503A (pt) 2004-06-23 2005-06-23 composição que compreende ácido lático e lactoferrina
NZ552764A NZ552764A (en) 2004-06-23 2005-06-23 Composition comprising lactic acid and lactoferrin
DE602005020639T DE602005020639D1 (de) 2004-06-23 2005-06-23 Zusammensetzung aus milchsäure und lactoferrin
US11/628,664 US20080161234A1 (en) 2004-06-23 2005-06-23 Composition Comprising Lactic Acid and Lactoferrin
ZA200703166A ZA200703166B (en) 2004-06-23 2005-06-23 Composition comprising lactic acid and lactoferrin
RU2007102273/15A RU2398575C2 (ru) 2004-06-23 2005-06-23 Композиция, содержащая молочную кислоту и лактоферрин
KR1020077001696A KR20070048170A (ko) 2004-06-23 2005-06-23 젖산 및 락토페린을 포함하는 조성물
CA002571183A CA2571183A1 (en) 2004-06-23 2005-06-23 Composition comprising lactic acid and lactoferrin
EP05755054A EP1784176B1 (en) 2004-06-23 2005-06-23 Composition comprising lactic acid and lactoferrin
JP2007518008A JP2008503576A (ja) 2004-06-23 2005-06-23 乳酸およびラクトフェリンを含む組成物
CNA2005800206978A CN1972683A (zh) 2004-06-23 2005-06-23 包含乳酸和乳铁传递蛋白的组合物
AU2005257722A AU2005257722B2 (en) 2004-06-23 2005-06-23 Composition comprising lactic acid and lactoferrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401631A SE528337C2 (sv) 2004-06-23 2004-06-23 Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet

Publications (3)

Publication Number Publication Date
SE0401631D0 SE0401631D0 (sv) 2004-06-23
SE0401631L true SE0401631L (sv) 2005-12-24
SE528337C2 SE528337C2 (sv) 2006-10-24

Family

ID=32768753

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401631A SE528337C2 (sv) 2004-06-23 2004-06-23 Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet

Country Status (15)

Country Link
US (1) US20080161234A1 (sv)
EP (1) EP1784176B1 (sv)
JP (1) JP2008503576A (sv)
KR (1) KR20070048170A (sv)
CN (1) CN1972683A (sv)
AT (1) ATE464045T1 (sv)
AU (1) AU2005257722B2 (sv)
BR (1) BRPI0512503A (sv)
CA (1) CA2571183A1 (sv)
DE (1) DE602005020639D1 (sv)
NZ (1) NZ552764A (sv)
RU (1) RU2398575C2 (sv)
SE (1) SE528337C2 (sv)
WO (1) WO2006001766A1 (sv)
ZA (1) ZA200703166B (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100801891B1 (ko) * 2006-11-02 2008-02-12 한상진 천연물질을 이용한 생식기 염증 예방 또는 치료용 약제학적 조성물
ES2482190T3 (es) * 2007-03-30 2014-08-01 Laccure Ab Uso de oligómeros de ácido láctico en el tratamiento de infecciones ginecológicas
EP2130531A1 (en) * 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
WO2010084038A1 (en) * 2009-01-23 2010-07-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Controlled release pharmaceutical or food formulation and process for its preparation
KR101133723B1 (ko) * 2009-10-19 2012-04-09 최원석 소금 및 당을 유효성분으로 함유하는 질염 예방 및 치료용 조성물 및 이의 용도
WO2012031186A1 (en) 2010-09-03 2012-03-08 Wisconsin Pharmacal Company, Llc. Prebiotic suppositories
CN104470498B (zh) * 2012-07-16 2017-08-08 莱克瑞股份公司 含有低聚乳酸的药物组合物
ITMI20122152A1 (it) * 2012-12-17 2014-06-18 Progine Farmaceutici S R L Composizione per uso topico.
EP2992894A1 (en) * 2014-09-05 2016-03-09 Progine Farmaceutici Srl Vaginal formulations for preventing and treating vaginal and cervico-vaginal infections
RU2637649C2 (ru) * 2014-10-30 2017-12-05 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) Способ и реагент-индикатор для рН-метрии вагинальной жидкости
MX2017016991A (es) * 2017-12-20 2019-06-21 Centro De Retina Medica Y Quirurgica S C Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos.
KR102683248B1 (ko) 2021-11-10 2024-07-10 장효영 질염 예방 및 치료를 위한 주입형 질 유산균 조성물
EP4260869A1 (en) * 2022-04-11 2023-10-18 Reckitt Benckiser Health Limited Composition comprising a combination of lactoferrin and a sulphated polysaccharide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8603338D0 (sv) * 1986-08-07 1986-08-07 Bjorn Andersch Medel for behandling av tillstand i slidan
DK0629347T3 (da) * 1992-01-23 1998-02-16 Morinaga Milk Industry Co Ltd Antibakterielt middel og behandling af genstande dermed
WO1998006425A1 (en) * 1996-08-12 1998-02-19 A+ Science Invest Ab Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin
CN1304313A (zh) * 1998-06-05 2001-07-18 若素制药株式会社 含乳酸菌的组合物、药物和食物
US6240320B1 (en) * 1998-06-05 2001-05-29 Intermedics Inc. Cardiac lead with zone insulated electrodes
JP3439686B2 (ja) * 1999-03-30 2003-08-25 雪印乳業株式会社 鉄強化飲料
IT1317937B1 (it) * 2000-11-17 2003-07-15 Sigma Tau Healthscience Spa Composizione per stimolare le difese immunitarie ed il metabolismo delferro comprendente una alcanoil l-carnitina e lattoferrina.

Also Published As

Publication number Publication date
AU2005257722A1 (en) 2006-01-05
CA2571183A1 (en) 2006-01-05
ZA200703166B (en) 2008-08-27
ATE464045T1 (de) 2010-04-15
JP2008503576A (ja) 2008-02-07
NZ552764A (en) 2010-03-26
SE528337C2 (sv) 2006-10-24
EP1784176B1 (en) 2010-04-14
US20080161234A1 (en) 2008-07-03
SE0401631D0 (sv) 2004-06-23
AU2005257722B2 (en) 2009-03-12
RU2007102273A (ru) 2008-07-27
CN1972683A (zh) 2007-05-30
EP1784176A1 (en) 2007-05-16
KR20070048170A (ko) 2007-05-08
WO2006001766A1 (en) 2006-01-05
DE602005020639D1 (de) 2010-05-27
BRPI0512503A (pt) 2008-03-11
RU2398575C2 (ru) 2010-09-10

Similar Documents

Publication Publication Date Title
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
SE0401631L (sv) Ny sammansättning
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
ATE546151T1 (de) Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
BRPI0511367A (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
WO2007134118A3 (en) Protein based composition and methods of using same
ATE524488T1 (de) Lysobactinamide
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
ATE444754T1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse

Legal Events

Date Code Title Description
NUG Patent has lapsed